Institutions

What did the research community enjoy most in 2019? Read Advarra's most popular blogs from industry experts and IRB members here.

Reportable events can be tricky: according to the regulations, not every unanticipated event should be submitted to the IRB.

Uncover what the regulations say about IRB reporting requirements and how Advarra has addressed some of the undefined gray areas around noncompliance.

Understand how the new HUD guidance clarifies responsibilites of the IRB and institutions, while widening the access of small communities to HUDs.

Social media has emerged as a valuable tool for diverse stakeholders across the research community. Learn about the risks and benefits in this article.

Learn how institutions attract more studies from the the tale of two sites: one with an integrated research administration, and one without.

Advarra attended the SCDM Annual Conference earlier this month, and took the time to reflect on the growth of the clinical data management domain.

What do the regulations say about unanticipated device effects and IRB reporting requirements? In this blog, Advarra addresses some frustrating gray areas.

Gene therapy research is at the forefront of a coming boom in the clinical setting. Understand the growth, risks, and regulatory requirements here.

On September 5, 2019, Advarra announced its intent to acquire Forte.

Participant compensation is often a complicated matter. This blog will shed light on what an IRB considers during its review.

Study-specific screening consent is a subtype of informed consent, which ensures a research participant understands of the research and its risks.